Format

Send to

Choose Destination
Acta Radiol. 2016 Nov;57(11):1396-1401. doi: 10.1177/0284185115586023. Epub 2016 Jul 21.

Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates.

Author information

1
1 Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
2
2 Washington National Primate Research Center, UW, Seattle, WA, USA.
3
3 Department of Urology, AMC University Hospital, Amsterdam, the Netherlands.
4
4 Urologic Oncology Branch, NCI, NIH, Bethesda, MD, USA.
5
5 Clinical Research Directorate/CMRP, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
6
6 Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.
7
7 Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA.
8
8 Center for Interventional Oncology, NCI and Radiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD, USA.
9
9 AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory, Frederick, MD, USA.

Abstract

Background A variety of magnetic resonance (MR) lymphographic agents have been proposed for mapping the lymph nodes draining the prostate. Purpose To investigate the feasibility of using ferumoxytol (an FDA-approved iron oxide agent) for lymph node mapping of the prostate on imaging (MRI) in a non-human primate (NHP) Macaque model. Material and Methods Four NHPs weighing 5-13 kg underwent injection of ferumoxytol after a needle was introduced transrectally under MRI guidance into the prostate using a commercially available intrarectal MRI biopsy guide. Ferumoxytol was administered at dosage in the range of 0.15-0.75 mg Fe/kg in a fixed injection volume of 0.2 mL. T1-weighted MRI was performed at 3 T starting immediately and extending at least 45 min post-injection. Two readers evaluated the images in consensus. The NHPs tolerated the ferumoxytol injections at all doses with no evident side effects. Results It was determined that the lowest dose of 0.15 mg Fe/kg produced the best outcome in terms of lymph node visualization and draining nodes were reliably visualized at this dose and volume. Conclusion Thus, MRI with intraprostatic injection of ferumoxytol may be considered an effective T1 contrast agent for prospective mapping of lymph nodes draining the prostate and, thus, for attempted sentinel lymph node identification in prostate cancer. Large clinical trials to determine safety and efficacy are needed.

KEYWORDS:

Ferumoxytol; iron oxide nanoparticles; lymph node; magnetic resonance imaging (MRI); prostate cancer

PMID:
26013022
PMCID:
PMC6301061
DOI:
10.1177/0284185115586023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center